FRIDAY, Jan. 2, 2026 -- For patients with hypertension , initiating treatment with an angiotensin receptor blocker (ARB) is associated with the best long-term class persistence, according to a study published online Dec. 19 in eClinicalMedicine . Karl Laurell, M.D., from Uppsala University in Sweden, and colleagues examined whether initiating treatment with a particular antihypertensive drug class will determine later persistence (defined as using dispensed prescription refills with at least 80

FRIDAY, Jan. 2, 2026 -- There is confusion regarding the purpose, implementation, and risk factors for early peanut introduction (EPI), although most parents of infants are at least partially aware of EPI guidelines, according to a study published online Dec. 18 in JAMA Network Open . Waheeda Samady, M.D., from Ann and Robert H. Lurie Children's Hospital of Chicago, and colleagues examined parental understanding, beliefs, barriers, and overall implementation of EPI. Semi-structured interviews we

FRIDAY, Jan. 2, 2026 — Severe asthma attacks can be cut in half among teens with excess weight by taking cutting-edge weight-loss drugs like Ozempic and Zepbound , a new study says. Half as many teens needed asthma treatment at an emergency room if they were on a GLP-1 drug, researchers reported Dec. 29 in JAMA Network Open . “Our findings suggest a potential dual benefit for this population, where a single class of medication could address both weight management and lower risk for asthma exace

DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported that it will provide an update on the status of its Investigational New Drug Application (IND) for GH001 with the U.S. Food and Drug Administration (FDA) and its global pivotal Phase 3 program in treatment-resistant depression (TRD) on Monday, January 5, 2026,

iStock, z_wei More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers reportedly plan to raise the U.S. prices of at least 350 branded medications. Drugmakers plan to raise the U.S. prices of 40% more drugs in 2026 than they did in 2025—despite pressure from President Donald Trump to charge less. Specifically, more than a dozen Big Pharmas have now reached Most Favored Nation agreements with the White House. Nevertheless, drug

Inspection of drug manufacturing sites in India is confidential information that is exempt from public disclosure under the Right to Information according to the drug regulatory authorities. Though the Central Drug Standards Control Organisation (CDSCO) is supposed to have started risk-based inspection of drug-making facilities since December 2022, when asked how many such inspections have been conducted each month since then the CDSCO claimed that the information was exempt under the RTI Act. H

New York: Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster ⁠cancer treatment Ibrance, even as the Trump administration pressures them for cuts, according to data provided exclusively by healthcare research firm 3 Axis Advisors . The number of price increases for 2026 is up from the same point last year, when drugmakers unveiled plans for raises on more than 250 drugs. The median of this year's price hikes

SINGAPORE, Jan. 1, 2026 /PRNewswire/ -- Boyang Wang, founder of Singapore-based longevity investment firm Immortal Dragons, has issued a public statement following his participation in a recent episode of the Financial Times' technology podcast series, Tech Tonic, titled "Defying Death: The Longevity Lab." Continue Reading Immortal Dragons Comments on Longevity Regulation and Investment Trends Following FT Podcast Appearance The episode examines Singapore's emergence as a global hub for longevit

DUBLIN--(BUSINESS WIRE)--The "Insomnia: Opportunity Assessment and Forecast Update" report has been added to ResearchAndMarkets.com's offering. This report covers the 7MM and provides an Excel-based forecast model for the Insomnia market through 2032. Z-drugs are the most common first-line treatment for insomnia across the US and 5EU. The insomnia pipeline in the 7MM is sparse but varied, containing products with varying mechanisms of action. There are five pipeline products in Phase II and III

2026 Expected to Be a Record Year AVACEN was founded by two military families. We have always helped our military community whenever possible. Our dream has continuously been to have an AVACEN device available to all Veterans in need.” — Danielle Forsgren, President CARLSBAD, CA, UNITED STATES, December 31, 2025 / EINPresswire.com / -- AVACEN Medical ® (AVACEN), a leading developer, manufacturer, and the #1 global distributor of noninvasive, FDA-Cleared Class II, palm-based, thermo-therapy medic